Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07138560 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease

Study acronym: BOOST-PD
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Dec 15, 2026 → Feb 15, 2027
See other at-risk trials from The Cleveland Clinic

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 15, 2026 to Feb 15, 2027 Show 4 more changesShow less
    • Study completion pushed from May 15, 2027 to Jun 15, 2027
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 1 of 5 entries
    • Publications: details revised at 3 of 3 entries
  2. Primary completion date: May 15, 2026 to Dec 15, 2026v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the effect of IPX203 (Crexont®) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms. 'Good on time' refers to a period (minutes to hours) when a patient experiences optimal symptom control due to effective medication and has better overall functioning without troublesome dyskinesias. The change in the duration and quality of on-time will be measured by a wearable device placed on your wrist called KinesiaU.
Trial Details
NCT Number NCT07138560
Lead Sponsor The Cleveland Clinic
Collaborators: Amneal Pharmaceuticals, LLC
Conditions
(from sponsor)		 Parkinson Disease
Related terms Parkinson Disease
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov